Clinical Trial

Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer

Study acronym: CAMELIA
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Exploring the Impact of body mass index on the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in advanced breast cancer.
Trial Details
NCT Number NCT06926088
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Advanced Breast Cancer
Enrollment 500 participants
Start Date 2016-12
Primary Completion 2025-12 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-04-13